AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

At the April Sampson Cancer Center on Monday, Tom Uhlman shared his story as part of the Shine a Light on Lung Cancer ...

Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

Calidi Biotherapeutics continues to advance its clinical-stage, off-the-shelf, virotherapies. With RTNova, the company is planning multi-modal systemic antitumor virotherapies that can disrupt tumor ...

Linda Chavez, 34, was diagnosed with Metastatic Bronchial Carcinoma, which has spread to her brain and bones. She regularly ...

Calidi (CLDI) Biotherapeutics presented data at the International Oncolytic Virotherapy Conference and the Society for Immunotherapy of Cancer Annual Meeting to support the targeted capabilities of ...

for use in certain patients with non-small cell lung cancer (NSCLC). The CHMP has recommended the Rybrevant-Lazcluze ...

Certain characteristics of the COVID-19 infection were associated with possible tumor shrinkage in patients with metastatic ...

FoundationOne Liquid CDx is now FDA-approved to identify mNSCLC patients with MET exon 14 skipping alterations for tepotinib ...

and often metastasizes to the lungs, liver, and bones. Approximately 20% of newly diagnosed cases of RCC are locally advanced or metastatic and up to 30% of patients will develop metastatic disease ...

The 22nd Annual Winter Lung Cancer Conference® will explore advances in neoadjuvant/adjuvant therapies. The FDA has approved Obe-cel for R/R B-ALL, and new treatments in SCLC, lurbinectedin and ...